Advancements in the fight against globally distributed OXA-48 carbapenemase: evaluating the new generation of carbapenemase inhibitors
Antimicrobial Agents and Chemotherapy · 13.02.2025 · 69 (2)
DOI: 10.1128/aac.01614-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 13.02.2025. Verfasst von Michelle Outeda-García und 16 weiteren Autor:innen. Beteiligte Einrichtung: Microbiology department, A Coruna University Hospital (CHUAC), Institute of Biomedical Research of A Coruna (INIBIC), A Coruna, Spain. Hauptthemen laut MEDLINE: beta-Lactamase Inhibitors, beta-Lactamases, Anti-Bacterial Agents, Bacterial Proteins. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MEC | Instituto de Salud Carlos III (ISCIII), Axencia Galega de Innovación, Spanish State Agency of Research.
Abstract (Originalsprache)
Carbapenemase OXA-48 and its variants pose a serious threat to the development of effective treatments for bacterial infections. OXA-48-producing Enterobacterales are the most prevalent carbapenemase-producing bacteria in large parts of the world. Although these bacteria exhibit low-level carbapenem resistance in vitro , the infections they cause are challenging to treat with conventional therapies, owing to their spread and complex detection in clinical settings. However, numerous β-lactamase inhibitors (BLIs) are currently in the pipeline or late clinical stages. To assess the potential of these compounds, this study compared the efficacy against OXA-48 of novel β-lactamase inhibitors, specifically the 1,6-diazabicyclo[3,2,1]octanes (DBOs) avibactam, relebactam, zidebactam, nacubactam, and durlobactam, along with the cyclic and bicyclic boronates vaborbactam, taniborbactam, and xeruborbactam. The extensive kinetics assays identified xeruborbactam, taniborbactam, and durlobactam, together with the already established avibactam, as BLIs with superior biochemical performance. Susceptibility testing further validated these findings but also demonstrated significantly improved bacterial killing by the DBOs zidebactam, nacubactam, and durlobactam. On the other hand, binding studies demonstrated the superior inhibitory capacity of the BLIs durlobactam and xeruborbactam. Combinations, such as cefepime/zidebactam, meropenem/nacubactam, and sulbactam/durlobactam, show promising activity against OXA-48-producing Enterobacterales, while ceftazidime/avibactam, cefepime/taniborbactam, and meropenem/xeruborbactam combinations also appear highly active, largely due to the excellent kinetics of these new inhibitors. Overall, this comprehensive analysis provides important insights into the effectiveness of new BLIs against OXA-48-producing Enterobacterales, highlighting xeruborbactam, durlobactam, and avibactam as leading candidates. Additionally, BLIs like zidebactam, nacubactam, and taniborbactam also showed potential in addressing the clinical challenges posed by OXA-48-mediated antimicrobial resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Microbiology department, A Coruna University Hospital (CHUAC), Institute of Biomedical Research of A Coruna (INIBIC), A Coruna, Spain.
- CIBER de Enfermedades Infecciosas (CIBERINFEC), A Coruna, Spain.
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela, Jenaro de la Fuente s/n, Santiago de Compostela, Spain.
ORCID-Profile: Michelle Outeda-García, Jorge Arca-Suárez, Cristina Lasarte-Monterrubio, Juan Carlos Vázquez-Ucha, German Bou, Alejandro Beceiro
Förderung
- MEC | Instituto de Salud Carlos III (ISCIII)
- Axencia Galega de Innovación
- Spanish State Agency of Research
- Xunta de Galicia
Zitieren
APA
Outeda-García, M., Arca-Suárez, J., Lence, E., Rodriguez-Coello, A., Maceiras, R., Blanco-Martin, T., Guijarro-Sánchez, P., Gonzalez-Pinto, L., Alonso-Garcia, I., García-Pose, A., Muras, A., Rodriguez-Pallares, S., Lasarte-Monterrubio, C., Gonzalez-Bello, C., Vázquez-Ucha, J. C., Bou, G., & Beceiro, A. (2025). Advancements in the fight against globally distributed OXA-48 carbapenemase: evaluating the new generation of carbapenemase inhibitors. Antimicrobial Agents and Chemotherapy, 69(2). https://doi.org/10.1128/aac.01614-24
Vancouver
Outeda-García M, Arca-Suárez J, Lence E, Rodriguez-Coello A, Maceiras R, Blanco-Martin T, et al. Advancements in the fight against globally distributed OXA-48 carbapenemase: evaluating the new generation of carbapenemase inhibitors. Antimicrobial Agents and Chemotherapy. 2025;69(2). doi:10.1128/aac.01614-24
BibTeX
@article{OutedaGarca2025,
author = {Outeda-García, Michelle and Arca-Suárez, Jorge and Lence, Emilio and Rodriguez-Coello, Arianna and Maceiras, Romina and Blanco-Martin, Tania and Guijarro-Sánchez, Paula and Gonzalez-Pinto, Lucia and Alonso-Garcia, Isaac and García-Pose, Andrea and Muras, Andrea and Rodriguez-Pallares, Salud and Lasarte-Monterrubio, Cristina and Gonzalez-Bello, Concepción and Vázquez-Ucha, Juan Carlos and Bou, German and Beceiro, Alejandro},
title = {Advancements in the fight against globally distributed OXA-48 carbapenemase: evaluating the new generation of carbapenemase inhibitors},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
volume = {69},
number = {2},
doi = {10.1128/aac.01614-24}
}
EUVIMED